Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if GANX is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
7 top institutions tracked
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoverySentiment: unknown
No recent insider trades detected.
Red flags: 0
50 filers reported a long position in GANX for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| MARSHALL WACE, LLP | $3.9M | 1.9M | +8.7% |
| Potomac Capital Management, Inc. | $1.9M | 946.4K | -6.2% |
| GSA CAPITAL PARTNERS LLP | $1.3M | 632.1K | +102.3% |
| Cambridge Investment Research Advisors, Inc. | $1.2M | 568.6K | Unchanged |
| DME Capital Management, LP | $1.1M | 566.1K | Unchanged |
| JONES FINANCIAL COMPANIES LLLP | $1.1M | 608.6K | -3.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | $974.9K | 480.3K | +20.1% |
| GEODE CAPITAL MANAGEMENT, LLC | $921.4K | 453.5K | +1.4% |
| BlackRock, Inc. | $558.2K | 275K | +22.2% |
| VANGUARD FIDUCIARY TRUST CO | $470K | 231.5K | +0.7% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.